<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846920</url>
  </required_header>
  <id_info>
    <org_study_id>6482-018</org_study_id>
    <secondary_id>MK-6482-018</secondary_id>
    <nct_id>NCT04846920</nct_id>
  </id_info>
  <brief_title>A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)</brief_title>
  <official_title>A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of&#xD;
      escalating doses of belzutifan as second line positive (2L+) treatment in participants with&#xD;
      advanced clear cell renal cell carcinoma (ccRCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">July 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The &quot;Belzutifan 160 mg BID&quot;, &quot;Belzutifan 160 mg TID&quot; and &quot;Belzutifan 200 mg TID&quot; study arms will be enrolled sequentially; the &quot;Belzutifan 120 mg QD&quot; study arm will be enrolled in parallel to the &quot;Belzutifan 160 mg BID&quot;, &quot;Belzutifan 160 mg TID&quot; and &quot;Belzutifan 200 mg TID&quot; arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Adverse Event (AE)</measure>
    <time_frame>Up to ~49.5 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience at least one AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinue Study Treatment Due to an AE</measure>
    <time_frame>Up to ~48.5 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Modify or Interrupt Study Treatment Due to an AE</measure>
    <time_frame>Up to ~48.5 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who modify or interrupt study treatment due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to ~21 days</time_frame>
    <description>A DLT consists of one or more of the following toxicities: (1) Grade 3 or 4 hypoxia or dyspnea (2) Grade 3 or 4 nausea, vomiting, or diarrhea if persistent for &gt;48 hours despite therapy (3) Grade 3 or 4 cardiovascular, vascular, or thrombotic events (4) Nonhematologic AE ≥Grade 3 in severity (5) Grade 4 nonhematologic toxicity (6) Grade 3 or 4 hematologic toxicities (7) Grade 3 or 4 febrile neutropenia (8) Grade 3 or 4 nonhematologic laboratory value (9) &gt;2 weeks delay in dosing due to intervention-related toxicity (10) Intervention-related toxicity causing intervention discontinuation in the first 21 days of dosing (11) Missing &gt;20% of belzutifan doses due to drug-related AEs in the first 21 days. (12) Grade 5 toxicity. The percentage of participants who experience at least one DLT will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve (AUC) of Belzutifan</measure>
    <time_frame>Day 1, Day 21: pre-dose, 0.5, 1, 1.5, 2, 4, and 6 hours post-dose; Day 2: pre-dose and 2 hours post-dose</time_frame>
    <description>AUC is a measure of plasma drug concentration and time and is estimated as the area under the plot of plasma concentration against time after belzutifan administration. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Belzutifan</measure>
    <time_frame>Day 1, Day 21: pre-dose, 0.5, 1, 1.5, 2, 4, and 6 hours post-dose; Day 2: pre-dose and 2 hours post-dose</time_frame>
    <description>Cmax is the maximum concentration of belzutifan observed in plasma. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of Belzutifan</measure>
    <time_frame>Day 1, Day 21: pre-dose, 0.5, 1, 1.5, 2, 4, and 6 hours post-dose; Day 2: pre-dose and 2 hours post-dose</time_frame>
    <description>Cmin is the minimum concentration of belzutifan observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples collected pre dose and at multiple timepoints post dose will be used to determine Cmin.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Belzutifan 160 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive belzutifan 160 mg orally twice daily (BID). Treatment will continue until progressive disease or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belzutifan 160 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive belzutifan 160 mg orally three times daily (TID). Treatment will continue until progressive disease or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belzutifan 200 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive belzutifan 200 mg orally TID. Treatment will continue until progressive disease or discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belzutifan 120 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive belzutifan 120 mg orally once daily (QD). Treatment will continue until progressive disease or discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belzutifan</intervention_name>
    <description>40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.</description>
    <arm_group_label>Belzutifan 120 mg QD</arm_group_label>
    <arm_group_label>Belzutifan 160 mg BID</arm_group_label>
    <arm_group_label>Belzutifan 160 mg TID</arm_group_label>
    <arm_group_label>Belzutifan 200 mg TID</arm_group_label>
    <other_name>MK-6482</other_name>
    <other_name>PT2977</other_name>
    <other_name>WELIREG™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically-confirmed diagnosis of unresectable, locally advanced/metastatic&#xD;
             RCC with clear cell component (with or without sarcomatoid features) (may include&#xD;
             participants with a diagnosis of von Hippel-Lindau [VHL] associated ccRCC).&#xD;
&#xD;
          -  Has experienced disease progression on or after having received at least one previous&#xD;
             systemic treatment for advanced ccRCC.&#xD;
&#xD;
          -  Shows adequate organ function.&#xD;
&#xD;
          -  Male participants are eligible to participate if they are abstinent from heterosexual&#xD;
             intercourse or agree to use contraception during the intervention period and for at&#xD;
             least 7 days after the last dose of study intervention.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and is not a woman of childbearing potential (WOCBP) or is a WOCBP and&#xD;
             using contraception or is abstinent from heterosexual intercourse during the&#xD;
             intervention period and for at least 30 days after the last dose of study&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has hypoxia, or requires intermittent supplemental oxygen, or requires chronic&#xD;
             supplemental oxygen.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years. Note: The time requirement does not apply to participants who&#xD;
             underwent successful definitive resection of basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical&#xD;
             cancer, or other in situ cancers.&#xD;
&#xD;
          -  Has any history of or current brain or meningeal metastasis.&#xD;
&#xD;
          -  Has clinically significant cardiac disease, including unstable angina, acute&#xD;
             myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or&#xD;
             coronary artery bypass graft surgery (CABG) ≤6 months from Day 1 of study drug&#xD;
             administration, or New York Heart Association Class III or IV congestive heart&#xD;
             failure. Medically controlled arrhythmia stable on medication is permitted.&#xD;
&#xD;
          -  Has moderate to severe hepatic impairment.&#xD;
&#xD;
          -  Has an active infection requiring therapy (includes tuberculosis).&#xD;
&#xD;
          -  Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections or is&#xD;
             known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus (HBV)&#xD;
             deoxy ribonucleic acid (DNA) or hepatitis C antibody or ribonucleic acid (RNA).&#xD;
&#xD;
          -  Has a history or current evidence of a gastrointestinal (GI) condition (eg,&#xD;
             inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver&#xD;
             function.&#xD;
&#xD;
          -  Has had major surgery ≤3 weeks prior to first dose of study intervention.&#xD;
&#xD;
          -  Has received prior treatment with belzutifan.&#xD;
&#xD;
          -  Has received any type of systemic anticancer antibody (including investigational&#xD;
             antibody) ≤4 weeks prior to the first dose of study intervention.&#xD;
&#xD;
          -  Has recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline.&#xD;
             Participants with a ≤ Grade 2 neuropathy may be eligible.&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks prior to randomization.&#xD;
&#xD;
          -  Has received colony-stimulating factors (CSFs) (e.g., granulocyte-CSF [G-CSF],&#xD;
             granulocyte monocyte-CSF [GM-CSF] or recombinant erythropoietin [EPO]) ≤28 days prior&#xD;
             to the first dose of study intervention.&#xD;
&#xD;
          -  Has participated and received study intervention in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study intervention. Note: Participants who have entered the follow-up phase of an&#xD;
             investigational study may participate as long as it has been at least 4 weeks since&#xD;
             the last dose of the previous investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center ( Site 1002)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-8543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan ( Site 1006)</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-764-8195</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-322-4967</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center-Genitourinary Medical Oncology ( Site 1007)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-563-1930</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia inducible factor (HIF)</keyword>
  <keyword>Hypoxia inducible factor 2 alpha (HIF-2α)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

